The History of Hormonal Contraception Johanna F Perlmutter, M.D. Assistant Professor Obstetrics, Gynecology and Reproductive Medicine Harvard Medical School 1827
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Johanna F Perlmutter, M.D.
Assistant Professor Obstetrics, Gynecology and Reproductive Medicine
Harvard Medical School
Benign Breast Disease
Functional ovarian cysts
Bone densityNoncontraceptive Health Benefits of Oral Contraceptives
Impact of Estrogen Dose
20-µg EE/1 mg NETA (n=102/459)
30-µg EE/1.5 mg NETA (n=117/494)
50-µg EE/1 mg NETA (n=100/441)
BTB/BTS Over 4 Treatment Cycles
Appel TB, Armon KA, Birdsall C, et al. Contraception. 1987;35:523-532.
Randomized, open-label, multicenter study
Delconte A, Loffer F, Grubb G. Contraception. 1999;59:187-193.
levonorgestrel 20 mcg/day
Abrams L, et al. FASEB J. 2000;14:A1479.
Fig. 2. Mean EE C-T curves for subjects (ASPE group) treated with NuvaRing (n=8), the transdermal contraceptive patch (n=6) and the COC (n=8).
If 1000 women have unprotected sex once in the second or third week of their cycle